Share this article:
Anti-Angiogenic Therapy and Cardiovascular Diseases – Drug Discovery and Development
We are proud to announce a group of new titles from Bentham Science are now available through Elsevier and ScienceDirect. To celebrate the release of these new titles we are offering a free chapter from the first of these valuable books, a clear review of drug discovery and development for cancer and cardiovascular disease.
Anti-Angiogenesis Drug Discovery and Development, Volume 2, edited by Atta ur-Rahman and Muhammad Iqbal Choudhary.
About this book: The discovery of angiogenic inhibitors is a promising approach for the treatment of various diseases, including cancers. The developments in this field are fast and exciting, this book covers many of these recent developments, reviewed by leading experts in cancer and cardiovascular medicinal chemistry.
Chapter 8: Anti-Angiogenic Therapy and Cardiovascular Diseases: Current Strategies and Future Perspectives
– Authored by Vasiliki K. Katsi, Costas T. Psarros, Marios G. Krokidis, Georgia D. Vamvakou, Dimitris Tousoulis, Christodoulos I. Stefanadis and Ioannis E. Kallikazaros
Anti-angiogenic therapy is a very dynamic field. In the future new, more potent drugs will be discovered, posing greater therapeutic potential and lower side effects, providing a much needed boost in this continuously evolving scientific field. This chapter focuses on the latest trends in antiangiogenic therapy and drug discovery as well as highlighting the distinct pathways underlying it.
Read below for this informative chapter and come back soon for further details and free content from recently published books in the Medicinal Chemistry.
Anti-Angiogenesis Drug Discovery and Development is available for purchase through the Elsevier store. Use discount code “STC215” at checkout and save up to 30% on your very own copy!
Access to this title is also available via ScienceDirect.
Elsevier and Bentham Science recently agreed to a distribution alliance, giving researchers greater access to needed chemistry content covering pharmaceutical science, medicinal chemistry, and other multi-disciplinary topics.
Along with Anti-Angiogenesis Drug Discovery and Development, two additional Bentham titles are now available through Elsevier:
– Drug Design and Discovery in Alzheimer’s Disease [formerly Frontiers in Drug Design and Discovery, Volume 6], edited by edited by Atta ur-Rahman and Muhammad Iqbal Choudhary. This book reviews developments in drug design for Alzheimer’s disease and related neurodegenerative disorders.
– Recent Advances in Medicinal Chemistry, Volume 1, edited by edited by Atta ur-Rahman, Muhammad Iqbal Choudhary, and George Perry. This book includes current research developments in pharmaceutical drug design and development.
About the Primary Series Editor:
Atta ur-Rahman, PhD, FRS, FPAS, is a Pakistani organic chemist and a leading scientist in the field of natural product chemistry, with approximately 983 publications to his name in the field of organic chemistry. He has edited more than 40 books published by Bentham Science and Elsevier
Look out for more from renowned expert Atta-ur-Rahman in September with the eagerly-awaited revision: Solving Problems with NMR Spectroscopy
It is impossible to imagine modern medicine without the continuing contributions of pharmaceutical science. This notably cross-disciplinary field, encompassing biomedical science, pharmacology, chemistry, microbiology, toxicology, genetics, and more, enables the discovery and development of drugs that millions of people depend on. Elsevier’s journals, books, eBooks and online solutions are used every day by researchers and industry professionals.